Live Breaking News & Updates on அன்னம் டால்மேன்

Stay updated with breaking news from அன்னம் டால்மேன். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Dermavant Sciences: Dermavant Announces Tapinarof Data Presentations at the AAD VMX 2021


Dermavant Sciences: Dermavant Announces Tapinarof Data Presentations at the AAD VMX 2021
Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that two abstracts from Dermavant s two pivotal Phase 3 trials for tapinarof for the treatment of psoriasis in adults, PSOARING 1 and PSOARING 2, will be presented during the upcoming American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX 2021), on April 23-25, 2021.
Tapinarof is being developed as a novel, once-daily therapeutic aryl hydrocarbon receptor modulating agent (TAMA), cosmetically elegant, steroid-free topical cream for the treatment of plaque psoriasis and atopic dermatitis.
The following posters will be viewable on the conference platform for the entirety of the conference: ....

United States , April Armstrong , Paul Yamauchi , Laurence Watts , Mark Lebwohl , Stephenc Piscitelli , Philipm Brown , Laurak Ferris , Bruce Strober , Josephf Merola , Annam Tallman , Robert Bissonnette , Angela Salerno Robin , Neal Bhatia , Kostenloser Wertpapierhandel , Howard Sofen , Lawrencej Green , Davids Rubenstein , Andrew Blauvelt , Seemalr Desai , American Academy Of Dermatology Virtual Meeting , Roivant Sciences , Program For Tapinarof , Dermavant Sciences , Linkedin Dermavant Sciences , American Academy ,

Dermavant Sciences: Dermavant Announces Tapinarof Data Presentation at the Innovations in Dermatology Conference


Dermavant Sciences: Dermavant Announces Tapinarof Data Presentation at the Innovations in Dermatology Conference
Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that an abstract containing interim analysis data from Dermavant s PSOARING 3 long-term, open-label safety study for tapinarof for the treatment of psoriasis in adults will be presented in poster format during the upcoming Innovations in Dermatology Virtual Spring Conference 2021, held from March 16-20, 2021.
The following poster will be viewable on the conference platform for the entirety of the conference:
Title:
Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Interim Analysis of a Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent ....

United States , Bruce Strober , April Armstrong , Laurence Watts , Annam Tallman , Robert Bissonnette , Mark Lebwohl , Angela Salerno Robin , Philipm Brown , Kostenloser Wertpapierhandel , Kara Stancell , Andrew Blauvelt , Roivant Sciences , Program For Tapinarof , Dermavant Sciences , Linkedin Dermavant Sciences , Investor Relations Corporate Communications , Dermatology Virtual Spring Conference , Tapinarof Cream , Once Daily , Plaque Psoriasis , Interim Analysis , Long Term Extension Trial , Linda Stein Gold , Leon Kircik , North America ,